For example, Loupakis and colleagues described a case in which a patient harbouring a metastatic CRC tumour characterized by MMR heterogeneity and treated with nivolumab and ipilimumab experienced prolonged disease control [75]. This evidence concerns the gene MRC1 and colorectal carcinoma.